Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

4D MOLECULAR THERAPEUTICS, INC.

(FDMT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

4D Molecular Therapeutics : Goldman Sachs Starts 4D Molecular Therapeutics at Neutral With $44 Price Target

01/05/2021 | 07:07am EST


ę MT Newswires 2021
All news about 4D MOLECULAR THERAPEUTICS, INC.
11/234D Molecular Therapeutics to Participate in the Upcoming Evercore ISI HealthCONx 2021 C..
AQ
11/104D Molecular Therapeutics Reports Financial Results for the Third Quarter of 2021 and P..
PU
11/104D MOLECULAR THERAPEUTICS INC. Management's Discussion and Analysis of Financial Condi..
AQ
11/104D Molecular Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine..
CI
11/10Earnings Flash (FDMT) 4D MOLECULAR THERAPEUTICS Reports Q3 Revenue $1.4M
MT
11/104D Molecular Therapeutics Reports Financial Results for the Third Quarter of 2021 and P..
AQ
10/294D Molecular Therapeutics Prices Stock Offering at $25 Per Share; Shares Decline
MT
10/294D Molecular Therapeutics Prices Stock Offering at $25 Per Share
MT
10/284D Molecular Therapeutics Announces Pricing of Public Offering of Common Stock
GL
10/274D Molecular Therapeutics Commences Public Offering of 4.5 Million Common Shares
MT
More news
Analyst Recommendations on 4D MOLECULAR THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2021 18,3 M - -
Net income 2021 -71,7 M - -
Net cash 2021 318 M - -
P/E ratio 2021 -9,09x
Yield 2021 -
Capitalization 750 M 750 M -
EV / Sales 2021 23,6x
EV / Sales 2022 358x
Nbr of Employees 121
Free-Float 90,4%
Chart 4D MOLECULAR THERAPEUTICS, INC.
Duration : Period :
4D Molecular Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends 4D MOLECULAR THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 23,35 $
Average target price 50,33 $
Spread / Average Target 116%
EPS Revisions
Managers and Directors
David H. Kirn President, Chief Executive Officer & Director
August J. Moretti Chief Financial Officer
John F. Milligan Executive Chairman
Melissa Kotterman Vice President-Discovery & Engineering
Fred Kamal Chief Operating & Technical Officer
Sector and Competitors
1st jan.Capi. (M$)
4D MOLECULAR THERAPEUTICS, INC.-43.67%750
MODERNA, INC.171.27%114 904
LONZA GROUP AG30.52%59 816
IQVIA HOLDINGS INC.51.92%51 999
SEAGEN INC.-14.61%27 346
CELLTRION, INC.-42.20%24 169